Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 85, Issue 3 PART A, 2013, Pages 550-559

  Pawar, Dilip ^a,b   Mangal, Sharad ^b   Goswami, Roshan ^b   Jaganathan, K S ^b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b Shantha Biotechnics Limited   (India)

Author keywords

Drug Delivery; Glycol chitosan; Hepatitis B surface antigen; Mucosal immunization; PLGA nanoparticles; Single shot vaccine

Indexed keywords

ANTIGEN; CHITOSAN COATED POLYGLACTIN NANOPARTICLE; GLYCOL CHITOSAN COATED POLYGLACTIN NANOPARTICLE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MUCIN; NANOPARTICLE; POLYGLACTIN; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COATED PARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MATERIAL COATING; MOUSE; MUCOADHESION; NASAL VACCINE DELIVERY; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PROTEIN ANALYSIS; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SYSTEMIC CIRCULATION; ZETA POTENTIAL;

DRUG DELIVERY; GLYCOL CHITOSAN; HEPATITIS B SURFACE ANTIGEN; MUCOSAL IMMUNIZATION; PLGA NANOPARTICLES; SINGLE SHOT VACCINE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHITOSAN; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNITY, MUCOSAL; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; RABBITS; TISSUE DISTRIBUTION;

EID: 84888324246     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.06.017     Document Type: Article

References (52)

1. M. Vajdy, and D.T. O'Hagan Microparticles for intranasal immunization Adv. Drug Del. Rev. 51 2001 127 141
2. J.M. Kyd, A.R. Foxwell, and A.W. Cripps Mucosal immunity in the lung and upper airway Vaccine 19 2001 2527 2533
3. M.R. Neutra, A. Frey, and J.P. Kraehenbuhl Epithelial M cells: gateways for mucosal infection and immunization Cell 86 1996 345 348
4. I. van der Ven, and T. Sminia The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study Reg. Immunol. 5 1993 69 75
5. R.J. Soane, M. Ferier, A.C. Perkins, N.S. Jones, S.S. Davis, and L. Illum Evaluation of the clearance characteristics of bioadhesive system in humans Int. J. Pharm. 178 1999 55 65
6. R.J. Soane, M. Hinchcliffe, S.S. Davis, and L. Illum Clearance characteristics of chitosan based formulation in the sheep nasal cavity Int. J. Pharm. 217 2001 183 191
7. L. Illum Nasal drug delivery-possibilities, problems and solutions J. Control. Release 87 2003 187 198
8. H.Y. Wu, and M.W. Russel Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant Vaccine 16 1998 286 292
9. Y. Perrie, P.M. Frederik, and G. Gregoriadis Liposome-mediated DNA vaccination: the effect of vesicle composition Vaccine 19 2001 3301 3310
10. J.J. Treanor, K. Kotloff, R.F. Betts, R. Belshe, F. Newman, and D. Iacuzio Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2) and B viruses Vaccine 18 2000 899 906
11. J.E. Eyles, E.D. Williamson, and H.O. Alpar Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume Int. J. Pharm. 189 1999 75 79
12. M. Koping-Hoggard, A. Sanchez, and M.J. Alonso Nanoparticles as carriers for nasal vaccine delivery Expert Rev. Vaccines 4 2005 185 196
13. L. Shi, M.J. Caulfield, R.T. Chern, R.A. Wilson, G. Sanyal, and D.B. Volkin Pharmaceutical and immunological evaluation of a single shot hepatitis B vaccine formulated with PLGA microspheres J. Pharm. Sci. 91 2002 1019 1035
14. K.S. Jaganathan, and S.P. Vyas Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally Vaccine 24 2006 4201 4211
15. D. Pawar, A.K. Goyal, S. Mangal, N. Mishra, B. Vaidya, S. Tiwari, A.K. Jain, and S.P. Vyas Evaluation of mucoadhesive PLGA microparticles for nasal immunization AAPS J. 12 2010 130 137
16. A. Vila, A.S. anchez, C. Evora, I. Soriano, O. McCallioc, and M.J. Alonso PLA-PEG particles as nasal protein carriers: the influence of the particle size Int. J. Pharm. 292 2005 43 52
17. P. Artursson, T. Lindmark, S.S. Davis, and L. Illum Effect of chitosan on the permeability of monolayer of intestinal epithelial cells (Caco-2) Pharm. Res. 11 1994 1358 1361
18. G. Borchard, H.L. Lueßen, A.G. de Boer, J.C. Verhoef, C.M. Lehr, and H.E. Junginger The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan glutamate and carbomer on epithelial tight junctions in vitro J. Control. Release 39 1996 131 138
19. O. Felt, P. Buri, and R. Gurny Chitosan: a unique polysaccharide for drug delivery Drug Dev. Ind. Pharm. 24 1998 979 993
20. A.F. Kotzé, M.M. Thanou, H.L. Luessen, B.G. de Boer, J.C. Verhoef, and H.E. Junginger Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2) Eur. J. Pharm. Biopharm. 47 1999 269 274
21. H.C. Arca, M. Günbeyaz, and S. Senel Chitosan-based systems for the delivery of vaccine antigens Expert Rev. Vaccines 8 2009 937 953
22. M. Werle, H. Takeuchi, and A. Bernkop-Schnürch Modified chitosans for oral drug delivery J. Pharm. Sci. 98 2009 1643 1656
23. V.K. Mourya, and Nazma N. Inamdar Chitosan-modifications and applications: opportunities galore React. Funct. Polym. 68 2008 1013 1051
24. S. Gogev, K. de Fays, M.F. Versali, S. Gautier, and E. Thiry Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1 Vaccine 22 2004 1946 1953
25. A. Trapania, J. Sitterberg, U. Bakowsky, and T. Kissel The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs Int. J. Pharm. 375 2009 97 106
26. A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein, and I. Uchegbu Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles Mol. Pharm. 9 2012 14 28
27. N. Duhem, J. Rolland, R. Riva, P. Guillet, J.M. Schumers, C. Jérome, J.F. Gohy, and V. Préat Tocol modified glycol chitosan for the oral delivery of poorly soluble drugs Int. J. Pharm. 28 2012 452 460
28. C. Keijzer, B. Slütter, R. van der Zee, W. Jiskoot, W. van Eden, and F. Broere PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity PLoS One 11 2011 e26684
29. P. Paolicelli, C. Prego, A. Sanchez, and M.J. Alonso Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles Nanomedicine (Lond) 5 2010 843 853
30. N. Nafee, S. Taetz, M. Schneider, U.F. Schaefer, and C.M. Lehr Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides Nanomedicine 3 2007 173 183
31. M. Singh, X. Li, J.P. McGhee, T. Zamb, W. Koff, C.Y. Wang, and D.T. O'Hagan Controlled release microparticles as a single dose Hepatitis B vaccine: evaluation of immunogenicity in mice Vaccine 15 1997 475 481
32. D.P. Joshi, Y.L. Lan-Chun-Fung, and J.G. Pritchard Determination of poly(vinylalcohol) via its complex with boric acid and iodide Anal. Chim. Acta 104 1979 153 160
33. M. Amidi, S.G. Romeijn, G. Borchard, H.E. Junginger, W.E. Hennink, and W. Jiskoot Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system J. Control. Release 111 2006 107 116
34. N.R. Mathia, J. Timoszyk, P.I. Stetsko, J.R. Megill, R.L. Smith, and D.A. Wall Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats J. Drug Target. 10 2002 31 40
35. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
36. J. Filipovic-Grcic, N. Skalko-Basnet, and I. Jalsenjak Mucoadhesive chitosan-coated liposomes: characteristics and stability J. Microencapsul. 18 2001 3 12
37. P. He, S.S. Davis, and L. Illum In vitro evaluation of the mucoadhesive properties of chitosan microspheres Int. J. Pharm. 166 1998 75 88
38. C.S. Chong, M. Cao, W.W. Wong, K.P. Fischer, W.R. Addison, G.S. Kwon, D.L. Tyrrell, and J. Samuel Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery J. Control. Release 102 2005 85 99
39. A. Debin, R. Kravtzoff, J.V. Santiago, L. Cazales, S. Sperandio, K. Melber, Z. Janowicz, D. Betbeder, and M. Moynier Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses Vaccine 20 2002 2752 2763
40. S. Jain, P. Singh, V. Mishra, and S.P. Vyas Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B Immunol. Lett. 101 2005 41 49
41. S. Sachdeva, G. Ahmad, P. Malhotra, P. Mukherjee, and V.S. Chauhan Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 119 and 42 kDa fragments expressed in Escherichia coli Infect. Immun. 70 2004 5775 5785
42. M.F. Zambaux, F. Bonneaux, R. Gref, P. Maincent, E. Dellacherie, M.J. Alonso, P. Labrude, and C. Vigneron Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method J. Control. Release 50 1998 31 40
43. S.K. Sahoo, J. Panyam, S. Prabha, and V. Labhasetwar Residual polyvinyl alcohol associated with poly(dl-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake J. Control. Release 82 2002 105 114
44. A.K. Jain, A.K. Goyal, P.N. Gupta, K. Khatri, N. Mishra, A. Mehta, S. Mangal, and S.P. Vyas Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B J. Control. Release 136 2009 161 169
45. K.S. Jaganathan, P. Singh, D. Prabakaran, V. Mishra, and S.P. Vyas Development of a single-dose stabilized poly(d,l-lactic-coglycolic acid) microspheres-based vaccine against hepatitis B J. Pharm. Pharmacol. 56 2004 1243 1250
46. A. Shenderova, T.G. Burke, and S.P. Schwendeman The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins Pharm. Res. 16 1999 241 248
47. G. Zhu, S.R. Mallery, and S.P. Schwendeman Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) Nat. Biotechnol. 18 2000 52 57
48. B.I. Florea, C. Meaney, H.E. Junginger, and G. Borchard Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell culture AAPS Pharm. Sci. 4 2002 E12
49. I. Gutierro, R.M. Hernandez, M. Igartua, A.R. Gascon, and J.L. Pedraz Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres Vaccine 21 2002 67 77
50. Y. Huang, and M.D. Donovan Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption Adv. Drug Deliv. Rev. 29 1998 147 155
51. M. Tob Io, R. Gref, A. Sanchez, R. Langer, and M.J. Alonso Stealth PEG-PLA nanoparticles as protein carriers for nasal administration Pharm. Res. 15 1998 270 275
52. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2006 148 158